The High-throughput Screening Core Facility (HTSCF) was established in 2003 to support the Institution's growth in chemical biology and functional genomics. The HTSCF's ongoing mission continues to support such efforts. Bioactive compounds are used as chemical tools to probe biological processes. The identification of novel molecules requires a broad range of tools including robust assays, large collections of chemicals, HTS technologies, and knowledge in hit validation and characterization steps. The HTSCF has modern robotics, custom built screening data management databases, chemical screening libraries, RNAi screening libraries, assay development and industrialization expertise, screening data analysis and management. The Core is equipped with two custom-built linear track robotic platforms harboring several dispensers, microtiter plate readers, automated microscopes among other instrumentation enabling both invitro target based and cell based assays to be routinely performed. Screening data acquisition and management is handled through a suite of custom built software. The compound library has grown to 400K chemicals;and contains a wide variety of natural products. The RNAi libraries have also grown to include both siRNA and shRNA capabilities covering 22K genes. Glycerol stocks of individual shRNA hairpins are provided as a service. One example of important work facilitated by this work was a screen against mutant EGFR in human lung cancer cell lines by the Varmus lab. The screening efforts led to the identification and characterization of four classes of small molecules overcoming the mutations. The broad range of services and collaborative work provided by the (HTSCF) has supported the research of 48 investigators in the past year. During the past grant period the work of the Core has contributed to 27 publications of researchers from 8 research programs.
The HTS Core facility provides investigators with access to two established chemical biology and functional genomic platforms;where discovered chemical molecules are used as probes to study biological processes, and Identified active gene(s) are further studied in the context of target validation for therapeutic intervention.
|Steuer, Conor E; Behera, Madhusmita; Berry, Lynne et al. (2016) Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer 122:766-72|
|Dominguez-Rosado, Ismael; Moutinho Jr, Vitor; DeMatteo, Ronald P et al. (2016) Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. J Am Coll Surg 222:961-6|
|Iasonos, Alexia; O'Quigley, John (2016) Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials 50:124-34|
|Brown, Anna M; Nagala, Sidhartha; McLean, Mary A et al. (2016) Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. Magn Reson Med 75:1708-16|
|Akkari, Leila; Gocheva, Vasilena; Quick, Marsha L et al. (2016) Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes Dev 30:220-32|
|Theilen, Till M; Chou, Alexander J; Klimstra, David S et al. (2016) Esophageal Adenocarcinoma and Squamous Cell Carcinoma in Children and Adolescents: Report of 3 Cases and Comprehensive Literature Review. J Pediatr Surg Case Rep 5:23-29|
|Robinson, June K; Halpern, Allan C (2016) Cost-effective Melanoma Screening. JAMA Dermatol 152:19-21|
|Calzavara-Pinton, Pier Giacomo; Rossi, Maria Teresa; Zanca, Arianna et al. (2016) Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study. Photodermatol Photoimmunol Photomed 32:22-7|
|Ripley, R Taylor; Suzuki, Kei; Tan, Kay See et al. (2016) Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg 151:969-77, 979.e1-3|
|Chapuis, Aude G; Roberts, Ilana M; Thompson, John A et al. (2016) T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol :|
Showing the most recent 10 out of 4768 publications